Pancreatic cancer is one of the most lethal malignancies worldwide. Although the standard
of care in pancreatic cancer has improved, prognoses for patients remain poor with a 5-year …

Pancreatic cancer is a major cause of cancer-associated mortality, with a dismal overall
prognosis that has remained virtually unchanged for many decades. Currently, prevention or …

Single-cell technologies have described heterogeneity across tissues, but the spatial
distribution and forces that drive single-cell phenotypes have not been well defined …

Pancreatic ductal adenocarcinoma (PDAC) constitutes one of the most challenging lethal
tumors and has a very poor prognosis. In addition to cancer cells, the tumor …

Pancreatic stellate cells (PSCs) were identified in the early 1980s, but received much
attention after 1998 when the methods to isolate and culture them from murine and human …

Pancreatic ductal adenocarcinoma (PDAC) remains a lethal cancer. The poor prognosis
calls for a more detailed understanding of disease biology in order to pave the way for the …

Pancreatic stellate cells (PSCs) are the major contributor to the aggressive, metastatic, and
resilient nature of pancreatic ductal adenocarcinoma (PDAC), which has a poor prognosis …

Pancreatic cancer is an extremely dismal malignance. Chemotherapy has been widely
applied to treat this intractable tumor. It has exclusive tumor microenvironment (TME) …

MET and its ligand HGF are involved in many biological processes, both physiological and
pathological, making this signaling pathway an attractive therapeutic target in oncology …

Pancreatic ductal adenocarcinoma (PDAC) is a gastrointestinal malignancy with a dismal
clinical outcome. Accumulating evidence suggests that activated pancreatic stellate cells …